Methods of treating allergy by administering interleukin-17 receptor
View Patent ↗Isolated receptors for IL-17, DNA's encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response.
1. A method for heating allergy, comprising administering to an individual having an allergy a composition comprising an effective amount of an Interleukin-17 receptor (IL-17R) protein selected from the group consisting of:
(a) a protein comprising amino acids 28 through 320 of SEQ ID NO:10;
(b) an analog of (a) that is at least 80% identical to amino acids 28 through 320 of SEQ ID NO:10, wherein said analog is soluble and has the capacity to bind IL-17; and
(c) a fragment of (a) or (b), wherein said fragment comprises the extracellular domain of the protein of SEQ ID NO:10 and binds IL-17;
and a suitable carrier.
2. The method of claim 1 , wherein the composition comprising an Interleukin-17 receptor protein comprises a protein comprising amino acids 28 through 320 of SEQ ID NO:10.
3. The method of claim 1 , wherein the composition comprising an Interleukin-17 receptor protein comprises an analog of a protein comprising amino acids 28 through 320 of SEQ ID NO:10 wherein said analog is at least 80% identical to amino acids 28 through 320 of SEQ ID NO:10, and wherein said analog protein is soluble and has the capacity to bind IL-17.
4. The method of claim 1 , wherein the composition comprising an Interleukin-17 receptor protein comprises a fragment of a protein comprising amino acids 28 through 320 of SEQ ID NO:10, wherein said fragment binds IL-17.
5. The method of claim 1 , wherein the composition comprising an Interleukin-17 receptor protein comprises a fragment of an analog of a protein comprising amino acids 28 trough 320 of SEQ ID NO: 10 wherein said analog is at least 80% identical to amino acids 28 through 320 of SEQ ID NO: 10, wherein said fragment of said analog comprises the extracellular domain of the protein of SEQ ID NO:10 and binds IL-17.
6. The method of claim 1 , wherein the Interleukin-17 receptor protein is a fusion protein.
7. The method of claim 6 , wherein the Interleukin-17 receptor protein is a Fc fusion protein.
8. The method of claim 7 , wherein the Interleukin-17 receptor Fc fusion protein comprises an IgG1 Fc domain.
9. The method of claim 8 , wherein the Interleukin-17 receptor IgG1 Fc fusion protein comprises a human IgG1 Fc domain.
10. The method of claim 9 , wherein the Interleukin-17 receptor human IgG1 Fc fusion protein comprises a human IgG1 Fc domain having the amino acid sequence of SEQ ID NO:4.
11. The method of claim 6 , wherein the Interleukin-17 receptor protein is an oligomeric Fc fusion protein.
12. The method of claim 6 , wherein the Interleukin-17 receptor fusion protein comprises a FLAG® peptide having the amino acid sequence of SEQ ID NO:3.
13. The method of claim 6 , wherein the fusion protein comprises an oligomerizing zipper domain linked to the Interleukin-17 receptor protein.
14. The method of claim 13 , wherein the oligomerizing zipper domain is a leucine zipper domain.
15. The method of claim 13 , wherein the fusion protein is oligomeric, such that the oligomeric fusion protein comprises at least two fusion proteins linked at the oligomerizing zipper domains.
16. The method of claim 15 , wherein the oligomerizing zipper domain is a leucine zipper domain.
17. The method of claim 1 , wherein the Interleukin-17 receptor protein is a non-glycosylated protein.
18. The method of any one of claims 1 , 2 , 3 , 4 and 16 , wherein the Interleukin-17 receptor protein is administered by bolus injection, continuous infusion and/or sustained release.